SYNERGY™ & SYNERGY MEGATRON™

EES PtCr Coronary Stent System

Because you never know when life will become complex

Drug-eluting stent technology has shown encouraging efficacy compared to bare metal stents, significantly reducing restenosis and revascularization procedures5. Still, there remains a concern for being able to treat ever-increasing complex lesions, ensuring proper healing, and managing dual antiplatelet therapy (DAPT).

What if there was a technology that offered the benefits of being able to improve the ability to acutely treat complex lesions, improve the healing properties, and potentially free selected patients from long-term DAPT?** 
 

Explore

Introducing the SYNERGY Stent

Designed to help patients, including those with complex cases, heal from day one and beyond.
 

Designed to Heal
 

Designed to Heal

Abluminally-coated stent technology synchronizes the release of drug elution and polymer absorption for optimal healing within the vessel.1

Early Healing
 

Early Healing

The SYNERGY Stent’s ultra-thin struts show more rapid healing compared to thicker stent strut designs in clinical cases and in preclinical research.2,3

Freedom from Long-Term Polymer Exposure

Freedom from Long-Term Polymer Exposure

Polymer is gone when it’s no longer needed—shortly after the drug is completely eluted at three months, which minimizes polymer exposure in the vessel.4

Complex Lesions

The SYNERGY Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease, including patients with acute myocardial infarction and patients with concomitant diabetes mellitus due to discrete de novo native coronary artery lesions.

The SYNERGY Stent System is also indicated for treatment of patients presenting with:

  • Acute coronary syndrome
  • Unstable angina
  • Renal failure
  • Coronary bifurcation lesions
  • Coronary multi-vessel disease
  • Coronary saphenous vein graft lesions
  • Coronary artery ostial lesions
  • Unprotected left main coronary artery lesions
  • Coronary artery total occlusion lesions
  • In-stent restenosis in coronary artery lesions
     

Ordering Information

SYNERGY BP Stent

Stent Length (mm)
ø 
(mm)
81216202428323848Over
Expansion
Capability
2.25H7493926208220H7493926212220H7493926216220H7493926220220H7493926224220H7493926228220H7493926232220H7493926238220 3.50
2.50H7493926208250H7493926212250H7493926216250H7493926220250H7493926224250H7493926228250H7493926232250H7493926238250H74939262482503.50
2.75H7493926208270H7493926212270H7493926216270H7493926220270H7493926224270H7493926228270H7493926232270H7493926238270H74939262482703.50
3.00H7493926208300H7493926212300H7493926216300H7493926220300H7493926224300H7493926228300H7493926232300H7493926238300H74939262483004.25
3.50H7493926208350H7493926212350H7493926216350H7493926220350H7493926224350H7493926228350H7493926232350H7493926238350H74939262483504.25
4.00H7493926208400H7493926212400H7493926216400H7493926220400H7493926224400H7493926228400H7493926232400H7493926238400H74939262484005.75
 4.50 H7493926212450H7493926216450H7493926220450
H7493926224450H7493926228450H7493926232450  5.75
5.00 H7493926212500H7493926216500H7493926220500H7493926224500H7493926228500H7493926232500  5.75
 

SYNERGY MEGATRON BP Stent

Stent Length (mm)

ø

(mm)

8121620242832Overexpansion Capabilities
3.50H7493942708350H7493942712350H7493942716350H7493942720350H7493942724350H7493942728350H74939427323506.0
4.00H7493942708400H7493942712400H7493942716400H7493942720400H7493942724400H7493942728400H74939427324006.0
4.50H7493942708450H7493942712450H7493942716450H7493942720450H7493942724450H7493942728450H74939427324506.0
5.00H7493942708500H7493942712500H7493942716500H7493942720500H7493942724500H7493942728500H74939427325006.0
 
Optimal Healing

Optimal Healing

Advanced design for optimal healing

Button
Clinical Program

Clinical Program

Addressing the full spectrum of cardiovascular disease complexity

Button
Real-World

Real-World Studies

How design impacts economic value

Button
Top